El Manar I, Tunisia

Riad Kharrat


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Riad Kharrat: Innovator in Therapeutic Applications of Maurocalcine

Introduction

Riad Kharrat is a notable inventor based in El Manar I, Tunisia. He has made significant contributions to the field of biochemistry, particularly in the development of therapeutic agents derived from natural toxins. His work focuses on the potential medical applications of Maurocalcine, a novel toxin isolated from the venom of the Tunisian chactidae scorpion.

Latest Patents

Riad Kharrat holds a patent for Maurocalcine and its analogues, which outlines their therapeutic uses. Maurocalcine has the amino acid sequence GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (SEQ. ID. No. 1). This compound is known for its ability to potently and reversibly modify the channel gating behavior of type 1 ryanodine receptor (RyR1). The research indicates that Maurocalcine and its bioactive structural analogues, particularly those containing the KKCKRR motif, have promising therapeutic potential. They may serve as candidate immuno-suppressive drugs and could be beneficial in treating pathologies in humans that involve calcium channel dysfunction.

Career Highlights

Riad Kharrat's career is marked by his innovative research and development in the field of pharmacology. His work has led to advancements in understanding how natural toxins can be harnessed for medical purposes. He is currently associated with Cellpep Pharma Inc., where he continues to explore the therapeutic applications of his discoveries.

Collaborations

Riad Kharrat collaborates with esteemed colleagues such as Kamel Mabrouk and Mohammed El-Ayeb. Their combined expertise enhances the research and development efforts at Cellpep Pharma Inc.

Conclusion

Riad Kharrat's contributions to the field of therapeutic applications of natural toxins, particularly through his work on Maurocalcine, highlight the potential of innovative research in medicine. His ongoing efforts at Cellpep Pharma Inc. promise to advance the understanding and treatment of calcium channel-related pathologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…